Drugs for Systolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 152)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Verapamil |
Approved |
Phase 4 |
|
152-11-4, 52-53-9 |
2520 |
Synonyms:
Akilen
Anpec
ANSYR
Ansyr®|CP-165331 / CP-16533-1|Securon®
Apo-verap
Arpamyl
Arpamyl LP
BERKATENS
CALAN
CALAN SR
Calaptin
Calaptin 240 SR
Calcan
Cardiabeltin
Cardiagutt
Cardibeltin
Cardioprotect
Caveril
Civicor
Civicor retard
Coraver
CORDILOX
CORDILOX I.V.
CORDILOX MR 240
Cordilox SR
Corpamil
COVERA
COVERA-HS
CP-165331
CP-16533-1
CP-165331 / CP-16533-1
CP-16533-1Calan
CP-165331Verapamil
D-365
D-365Iproveratril
delta-365
Dexverapamil
Dignover
Dilacoran
Dilacoran hta
Drosteakard
Durasoptin
Elthon
ETHIMIL MR 240
Falicard
Finoptin
Flamon
GEANGIN
HALF SECURON SR
Harteze
Hexasoptin
Hexasoptin retard
Hormitol
Hydrochloride, verapamil
Ikacor
Ikapress
Inselon
Iproveratril
Isoptimo
ISOPTIN
Isoptin retard
ISOPTIN SR
Isoptine
Isoptino
Isotopin
Izoptin
Jenapamil
Lekoptin
Lodixal
LU-20175
Magotiron
Manidon
Manidon retard
MANIDON SR
Novapamyl LP
Novo-veramil
|
NSC-272306NA
NSC-272366
NSC-657799
Nu-verap
Ormil
Praecicor
Quasar
RANVERA MR
Rapam
Robatelan
Sandoz brand OF verapamil
SECURON
SECURON IV
SECURON MID
SECURON SR
Tarka
UNIVER
Univex
Vasolan
Vasomil
Vasopten
Verabeta
Veracaps SR
Veracim
Veracor
Verahexal
Veraloc
Veramex
Veramil
Verapamil
Vérapamil
Verapamil [Usan:Ban:Inn]
Verapamil acis
Verapamil al
Verapamil atid
Verapamil basics
Verapamil ebewe
VERAPAMIL HCL
Verapamil henning
Verapamil hydrochloride
Verapamil injection
Verapamil MSD
Verapamil NM
Verapamil NM pharma
Verapamil nordic
Verapamil PB
Verapamil riker
Verapamil sandoz brand
Verapamil SR
Verapamil verla
Verapamil-abz
Verapamilo
Verapamilo [INN-Spanish]
Verapamilum
Verapamilum [INN-Latin]
Verapin
Verapress 240 SR
VERAPRESS MR 240
Veraptin
Verasal
Vera-sanorania
Verasifar
Veratensin
VERA-TIL SR
Verdilac
VERELAN
VERELAN PM
Verelan SR
Verexamil
Veroptinstada
Verpamil
VERTAB SR 240
Vetrimil
Vortac
ZOLVERA
|
|
2 |
|
Carvedilol |
Approved, Investigational |
Phase 4 |
|
72956-09-3 |
2585 |
Synonyms:
(+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol
14C-Labeled carvedilol
Artist
BM 14.190
BM-14.190
BM-14190
BM-14-190
C07AG02
CARVEDILOL
Carvédilol
Carvedilol hydrochloride
Carvedilol, (-)
Carvedilol, (-)-isomer
Carvedilol, (+)
Carvedilol, (+)-isomer
Carvedilol, (+-)-isomer
Carvedilol, (R)-isomer
Carvedilol, (S)-isomer
Carvedilol, 14C labeled
|
Carvedilol, 14C-labeled
Carvedilolum
Carvedilolum [Latin]
Coreg
COREG CR
Coreg®|DQ 2466|Eucardic®|SKF 105517
Coropres
Dilatrend
DQ 2466
DQ-2466
Eucardic
EUCARDIC 12.5
EUCARDIC 25
EUCARDIC 3.125
EUCARDIC 6.25
Kredex
Querto
SKF 105517
SKF-105517
|
|
3 |
|
Benzocaine |
Approved, Investigational |
Phase 4 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
4 |
|
Tannic acid |
Approved |
Phase 4 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
5 |
|
Lisinopril |
Approved, Investigational |
Phase 4 |
|
83915-83-7, 76547-98-3 |
5362119 |
Synonyms:
(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
[N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline
Acerbon
Acercomp
Alapril
Carace
Cipral
Cipril
Coric
Inhibril
Inopril
Linopril
Linvas
Lipril
Lisinal
LISINOPRIL
Lisinopril anhydrous
LISINOPRIL DIHYDRATE
LISINOPRIL HYDRATE
Lisinopril maleate (1:1)
Lisinopril sulfate (1:2)
Lisinoprilum
Lisipril
|
Lisoril
Lispril
Loril
LPR
Lysinopril
MK-521
Noperten
Novatec
Presiten
Prinil
Prinivil
Prinivil®|Zestril®
Prinzide
Renacor
Sinopril
Sinopryl
Tensopril
Tensyn
Tersif
Vivatec
Zestoretic
Zestril
|
|
6 |
|
Angiotensin II |
Approved, Investigational |
Phase 4 |
|
68521-88-0, 11128-99-7, 4474-91-3 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
Angiotonin
|
Asp-arg-val-tyr-ile-his-pro-phe
Delivert
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
7 |
|
Bisoprolol |
Approved |
Phase 4 |
|
66722-44-9 |
2405 |
Synonyms:
(+-)-1-((a-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
(+-)-1-((alpha-(2-Isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
(+-)-1-((Α-(2-isopropoxyethoxy)-p-tolyl)oxy)-3-(isopropylamino)-2-propanol
(RS)-1-(4-(2-Isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol
Bisoprolol
Bisoprolol fumarate
Bisoprolol fumarate (1:1) salt, (+-)-isomer
Bisoprolol fumarate (2:1) salt, (+-)-isomer
Bisoprolol fumerate
Bisoprolol hemifumarate
Bisoprolol hydrochloride
Bisoprolol methanesulfonate salt
Bisoprolol, (-)-isomer
Bisoprolol, (+-)-isomer
Bisoprolol, fumarate (1:1) salt
Bisoprolol, fumarate (2:1) salt
Bisoprololum
Cardicor
CL-297939
|
Concor
Condyline
Condylox
CONGESCOR
Detensiel
Emconcor
Emcor
EMD-33512
EMD-33-512
Euradal
Fumarate, bisoprolol
Hydrochloride, bisoprolol
Isoten
Merck brand OF bisoprolol fumarate
Monocor
Soloc
Soprol
ZEBETA
ZIAC
|
|
8 |
|
Canagliflozin |
Approved |
Phase 4 |
|
842133-18-0 |
74323022 24812758 |
Synonyms:
1-(GLUCOPYRANOSYL)-4-METHYL-3-(5-(4-FLUOROPHENYL)-2-THIENYLMETHYL)BENZENE
CANAGLIFLOZIN
CANAGLIFLOZIN ANHYDROUS
Canagliflozina
Invokana®|JNJ-28431754|TA-7284
|
JNJ-24831754-ZAE
JNJ-28431754
JNJ-28431754-AAA
TA-7284
|
|
9 |
|
Clopidogrel |
Approved |
Phase 4 |
|
120202-66-6, 113665-84-2 |
60606 |
Synonyms:
(+)-(S)-Clopidogrel
(+)-Clopidogrel
(S)-Clopidogrel
BMS Brand 1 OF clopidogrel bisulfate
BMS Brand 2 OF clopidogrel bisulfate
CLOPIDOGREL
Clopidogrel [Ban:Inn]
Clopidogrel besilate
Clopidogrel besylate
Clopidogrel bisulfate
Clopidogrel bisulphate
Clopidogrel hydrochloride
CLOPIDOGREL HYDROGEN SULFATE
Clopidogrel mepha
Clopidogrel napadisilate
|
Clopidogrel sandoz
CLOPIDOGREL SULFATE
Clopidogrel, (+)(S)-isomer
Clopidogrel-mepha
Clopidogrelum
GREPID
Iscover
Isocover
Plavix
PLAVIX®
R 130964
R-130964
SR 25990
SR-25990
SR-25990C
|
|
10 |
|
Valsartan |
Approved, Investigational |
Phase 4 |
|
137862-53-4 |
60846 |
Synonyms:
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
CGP-48933
CGP-48933|Diovan®|Prexxartan® (oral solution)
Diovan
EXFORGE
Kalpress
Miten
N-(p-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Nisis
|
N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-Valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
PREXXARTAN
Provas
Tareg
VAL489
Vals
VALSARTAN
|
|
11 |
|
Enalaprilat |
Approved |
Phase 4 |
|
76420-72-9 |
6917719 5462501 |
Synonyms:
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
Anhydrous enalaprilat citrate
Anhydrous, enalaprilat
Biovail brand OF enalaprilat anhydrous
Boehringer ingelheim brand OF enalaprilat anhydrous
Dihydrate, enalaprilat
Enalapril acid
Enalapril diacid
Enalapril teva
ENALAPRILAT
Enalaprilat anhydrous
Enalaprilat citrate, anhydrous
Enalaprilat dihydrate
Enalaprilat, (R)-isomer, anhydrous
|
Enalaprilate
Enalaprilatum
Enalaprilic acid
Enalapril-teva
EnalaprilTEVA
Merck frosst brand OF enalaprilat anhydrous
MK-421
MK-422
MSD Brand OF enalaprilat
N-[(1S)-1-Carboxy-3-phenylpropyl]-L-alanyl-L-proline
Pres IV
Teva brand OF enalaprilat
Vasotec
Xanef
|
|
12 |
|
Enalapril |
Approved, Vet_approved |
Phase 4 |
|
75847-73-3 |
40466924 5388962 5362032 |
Synonyms:
(S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylate
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
Analapril
ánalapril
Bonuten
C09AA02
ENALADEX
Enaladex®|Vasotec®
Enalapril
Enalapril Bp
Enalapril maleate
Enalapril Richet
Enalaprila
|
Enalaprila [INN-Spanish]
Enalaprilat
Enalaprilum
Enalaprilum [INN-Latin]
EPL753
Gadopril
Kinfil
LEXXEL
Maleate, enalapril
Renitec
Renitek
VASERETIC
VASOTEC
Vasotec IV
|
|
13 |
|
Hydralazine |
Approved |
Phase 4 |
|
86-54-4 |
3637 |
Synonyms:
(1Z)-1(2H)-Phthalazinone hydrazone
(2H)-Phthalazinone hydrazone
1-Hydrazinophthalazine
1-Phthalazinylhydrazine
6-Hydralazine
APR968
Apresoline
Apressin
Apressoline
Hidral
Hidralazina
Hydralazin
HYDRALAZINE
Hydralazine hydrochloride
|
Hydralazine mono hydrochloride
Hydralazine mono-hydrochloride
Hydralazinum
Hydrallazin
Hydrallazine
Hydrazinophthalazine
Hydrazone 1(2H)-phthalazinone
Hydrochloride, hydralazine
Hypophthalin
Idralazina
mono-Hydrochloride, hydralazine
Nepresol
NSC-126699
Phthalazin-1-ylhydrazine
|
|
14 |
|
Iron |
Approved |
Phase 4 |
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
15 |
|
Eplerenone |
Approved |
Phase 4 |
|
107724-20-9 |
443872 |
Synonyms:
9,11-Epoxy-7-(methoxycarbonyl)-3-oxo-17-pregn-4-ene-21,17-carbolactone
Eplerenon
Eplerenona
EPLERENONE
Epoxymexrenone
|
Inspra
Inspra®|SC-66110
SC-66110
SC-6611O
|
|
16 |
|
Spironolactone |
Approved |
Phase 4 |
|
1952-01-7, 52-01-7 |
5833 |
Synonyms:
ABBOLACTONE
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone a
Aldactone®|spiractin|spirotone
Alderon
Aldopur
Almatol
Alphapharm brand OF spironolactone
Alpharma brand OF spironolactone
Alter brand OF spironolactone
Altex
Aquareduct
Ashbourne brand OF spironolactone
Azupharma brand OF spironolactone
Betapharm brand OF spironolactone
Cardel brand OF spironolactone
CAROSPIR
CT Arzneimittel brand OF spironolactone
CT, Spiro von
CT-Arzneimittel brand OF spironolactone
Deverol
Dexo brand OF spironolactone
DIATENSEC
Dira
Duraspiron
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona alter
Espironolactona mundogen
Euteberol
Flumach
Frumikal
Generosan brand OF spironolactone
GX SPIRONOL
Hormosan brand OF spironolactone
Jenapharm brand OF spironolactone
Jenaspiron
Lacalmin
Lacdene
LARACTONE
Mayoly-spindler brand OF spironolactone
Melarcon
Merck dura brand OF spironolactone
Mundogen brand OF spironolactone
Nefurofan
Novo spiroton
Novopharm brand OF spironolactone
Novo-spiroton
NovoSpiroton
NSC-150399
Osyrol
Pfizer brand OF spironolactone
|
Pharmafrid brand OF spironolactone
Practon
Roche brand OF spironolactone
Sagisal
SC-9420
Searle brand OF spironolactone
Sincomen
SNL
Spiractin
Spiresis
SPIRETIC
Spiridon
SPIRNOLACTONE
Spiro l.u.t.
Spiro von CT
Spirobeta
Spiroctan
SPIROCTAN 100
SPIROCTAN 25
SPIROCTAN 50
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
Spirono isis
Spironocompren
Spirono-isis
SPIRONOLACTONE
Spironolactone [BAN:INN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
SPIROSPARE 100
SPIROSPARE 25
Spiro-Tablinen
SPIROTONE
Sprioderm
Supra-puren
Suracton
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
Von CT, spiro
Wörwag brand OF spironolactone
Xenalon
|
|
17 |
|
Simendan |
Investigational |
Phase 4 |
|
131741-08-7 |
|
Synonyms:
((4-(1,4,5,6-tetrahydro-4-Methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile
Dextrosimendan
Levosimendan
|
|
|
18 |
|
calcium channel blockers |
|
Phase 4 |
|
|
|
19 |
|
Angiotensin Receptor Antagonists |
|
Phase 4 |
|
|
|
20 |
|
Sacubitril and valsartan sodium hydrate drug combination |
|
Phase 4 |
|
|
|
21 |
|
Angiotensinogen |
|
Phase 4 |
|
|
16133225 |
Synonyms:
Hypertensinogen
Proangiotensin
Renin substrate
Renin substrate tetradecapeptide
|
Renin-substrate
Serpin a8
SERPINA8
Tetradecapeptide, renin substrate
|
|
22 |
|
HIV Protease Inhibitors |
|
Phase 4 |
|
|
|
23 |
|
Giapreza |
|
Phase 4 |
|
|
|
24 |
|
protease inhibitors |
|
Phase 4 |
|
|
|
Synonyms:
|
25 |
|
Adrenergic beta-1 Receptor Antagonists |
|
Phase 4 |
|
|
|
26 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
27 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
28 |
|
Sympatholytics |
|
Phase 4 |
|
|
|
29 |
|
Sitagliptin Phosphate |
|
Phase 4 |
|
654671-77-9 |
|
Synonyms:
JANUMET XR
JANUVIA
MK0431
MK-0431
ONO-5435
|
SITAGLIPTIN MONOPHOSPHATE ANHYDROUS
SITAGLIPTIN MONOPHOSPHATE MONOHYDRATE
SITAGLIPTIN PHOSPHATE
SITAGLIPTIN PHOSPHATE HYDRATE
SITAGLIPTIN PHOSPHATE MONOHYDRATE
|
|
30 |
|
Dipeptidyl-Peptidase IV Inhibitors |
|
Phase 4 |
|
|
|
31 |
|
Incretins |
|
Phase 4 |
|
|
|
32 |
|
Purinergic P2Y Receptor Antagonists |
|
Phase 4 |
|
|
|
33 |
|
Prasugrel Hydrochloride |
|
Phase 4 |
|
389574-19-0 |
|
Synonyms:
|
34 |
|
Platelet Aggregation Inhibitors |
|
Phase 4 |
|
|
|
35 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 4 |
|
|
|
36 |
|
Angiotensin-Converting Enzyme Inhibitors |
|
Phase 4 |
|
|
|
37 |
|
Chrysarobin |
|
Phase 4 |
|
|
|
38 |
|
Adrenergic beta-Antagonists |
|
Phase 4 |
|
|
|
39 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
40 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
41 |
|
Mineralocorticoids |
|
Phase 4 |
|
|
|
42 |
|
Mineralocorticoid Receptor Antagonists |
|
Phase 4 |
|
|
|
43 |
|
Hormones |
|
Phase 4 |
|
|
|
44 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
45 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
46 |
|
diuretics |
|
Phase 4 |
|
|
|
47 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
48 |
|
Cardiotonic Agents |
|
Phase 4 |
|
|
|
49 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
50 |
|
Phosphodiesterase 3 Inhibitors |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 187)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations |
Unknown status |
NCT03764722 |
Phase 4 |
Levosimendan |
2 |
Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial |
Unknown status |
NCT03096613 |
Phase 4 |
Levothyroxine |
3 |
Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial |
Unknown status |
NCT01612260 |
Phase 4 |
Shensong Yangxin capsule;placebo Capsule |
4 |
Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism |
Unknown status |
NCT02316743 |
Phase 4 |
Levothyroxine supplementation |
5 |
The Effect of Ferric Carboximaltose on Intra-myocardial Iron Load Assessed by Cardiac Magnetic Resonance in Patients With Heart Failure With Reduced Ejection Fraction (HFREF). |
Unknown status |
NCT03871699 |
Phase 4 |
Ferric carboxymaltose |
6 |
Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy |
Unknown status |
NCT00348530 |
Phase 4 |
Verapamil |
7 |
Metformin in Patients With Chronic and Acute Heart Failure: Pharmacokinetics and Polymorphisms in Genes Encoding Membrane Metformin Transporter Proteins |
Unknown status |
NCT02797340 |
Phase 4 |
Metformin |
8 |
Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial |
Unknown status |
NCT02579200 |
Phase 4 |
|
9 |
Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS® |
Unknown status |
NCT04570865 |
Phase 4 |
Dapagliflozin |
10 |
Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin. A Ringerike Heart Failure Cohort Phase IV Study of Angiotensin Receptor Neprilysin Inhibiton |
Unknown status |
NCT03553303 |
Phase 4 |
Sacubitril / Valsartan Oral Tablet |
11 |
Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study. |
Unknown status |
NCT03392740 |
Phase 4 |
Lisinopril;Placebo Oral Tablet |
12 |
Prospective, Open-labeled Trial in Patients With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM) |
Completed |
NCT01074307 |
Phase 4 |
Low Dose Bisoprolol;High Dose Bisoprolol |
13 |
A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure |
Completed |
NCT02920918 |
Phase 4 |
Canagliflozin;Sitagliptin |
14 |
Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure |
Completed |
NCT01765400 |
Phase 4 |
Prasugrel 10 mg daily x 2 weeks;Clopidogrel 75 mg daily x 2 weeks |
15 |
SASHFR (South Asian Systolic Heart Failure Registry) : A Multi-center, Nonrandomized, Prospective Study to Collect Data Pertaining to the Demographic and Cardiovascular Profiles, Management Strategies and Clinical Outcomes of HF Patients. |
Completed |
NCT01434615 |
Phase 4 |
|
16 |
Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure |
Completed |
NCT02903225 |
Phase 4 |
|
17 |
Dietary Nitrate Supplementation and Cardiorespiratory Control in Chronic Heart Failure: a Randomized, Placebo-controlled Trial |
Completed |
NCT02401126 |
Phase 4 |
|
18 |
Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction |
Completed |
NCT05387967 |
Phase 4 |
Sacubitril/valsartan |
19 |
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Ejection Fraction (AWAKE-HF). |
Completed |
NCT02970669 |
Phase 4 |
sacubitril/valsartan (LCZ696);enalapril;matching placebo sacubitril/valsartan (LCZ696);matching placebo enalapril |
20 |
The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation |
Recruiting |
NCT04217135 |
Phase 4 |
evidence-based medications vs. high-dose hydralazine + evidence-based medications |
21 |
Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality - FAIR-HF2 |
Recruiting |
NCT03036462 |
Phase 4 |
Iron;Saline |
22 |
Pulse Reduction On Beta-blocker and Ivabradine Therapy |
Active, not recruiting |
NCT02973594 |
Phase 4 |
Ivabradine;Placebo |
23 |
Cluster and Registry Trials Of the Working Group of Heart Failure in Denmark: Are SPironolactone and Eplerenone Comparable Treatments? |
Enrolling by invitation |
NCT03984591 |
Phase 4 |
Eplerenone;Spironolactone |
24 |
Levosimendan In Ambulatory Heart Failure Patients |
Not yet recruiting |
NCT04705337 |
Phase 4 |
Levosimendan |
25 |
Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure |
Unknown status |
NCT01913847 |
Phase 3 |
Sildenafil;Placebo |
26 |
Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets (FIRST) |
Unknown status |
NCT02188082 |
Phase 2, Phase 3 |
IvabRadine hemisulfate Sustained-release Tablets;placebo |
27 |
MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy |
Unknown status |
NCT01640769 |
Phase 3 |
|
28 |
Impact of Renal Artery Denervation in Patients With Chronic Heart Failure Compared With Sham Procedure |
Unknown status |
NCT01639378 |
Phase 3 |
|
29 |
The Effect of Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia |
Completed |
NCT02998697 |
Phase 2, Phase 3 |
Ferrous Sulfate;Placebo Oral Capsule |
30 |
Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure |
Completed |
NCT00206310 |
Phase 3 |
CRESTOR |
31 |
The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Subjects With NYHA Class II Chronic Systolic Heart Failure |
Completed |
NCT00232180 |
Phase 3 |
Eplerenone |
32 |
Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients |
Completed |
NCT02809131 |
Phase 3 |
polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline |
33 |
Spinal Cord Stimulation For Heart Failure As A Restorative Treatment |
Completed |
NCT01362725 |
Phase 2, Phase 3 |
|
34 |
A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Sacubitril/Valsartan Compared With Enalapril to Improve Erectile Function in Patients With Heart Failure With Reduced Ejection Fraction and Erectile Dysfunction |
Completed |
NCT03917459 |
Phase 3 |
LCZ696;Enalapril matching placebo;Enalapril;LCZ696 matching placebo |
35 |
Blended Collaborative Care for Heart Failure and Co-Morbid Depression |
Completed |
NCT02044211 |
Phase 2, Phase 3 |
|
36 |
Growth Hormone Treatment in Patients With Ischemic Heart Failure and Circulating Levels of NT-proBNP |
Completed |
NCT04420481 |
Phase 3 |
Somatropin;Placebo |
37 |
Cardiovascular Effects of Preferred Home-based Exercise Training and Extended Adherence Measures in Systolic Heart Failure - Pilot Study |
Recruiting |
NCT02051712 |
Phase 3 |
|
38 |
A Multi-center, Randomized, Double-blined, Placebo Parallel Controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Mortality of Subjects With Chronic Systolic Heart Failure on Standard HF Therapy. |
Recruiting |
NCT03388593 |
Phase 3 |
rhNRG-1;Placebo |
39 |
Investigator-initiated, Randomized, Double-blind, Controlled, Multi-center Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency |
Recruiting |
NCT03991000 |
Phase 3 |
Ferric carboxymaltose;Saline |
40 |
Mechanisms, Safety and Efficacy of Optimising Pacemaker Heart Rate for Contractility: Effects on Walk Time, Cardiac Remodelling and Quality of Life |
Recruiting |
NCT04201015 |
Phase 2, Phase 3 |
|
41 |
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure on Standard Heart Failure Therapy |
Active, not recruiting |
NCT04468529 |
Phase 3 |
Recombinant human Neuregulin for injection;Placebo |
42 |
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure |
Terminated |
NCT01131637 |
Phase 3 |
rhNRG-1;placebo |
43 |
Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure |
Terminated |
NCT01646515 |
Phase 3 |
Placebo;Udenafil (Zydena) |
44 |
A Multi-center, Randomized, Double-blind , Placebo Parallel Controlled, Standard Therapy Based Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure |
Terminated |
NCT01214096 |
Phase 3 |
rhNRG-1;placebo |
45 |
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure |
Terminated |
NCT01439789 |
Phase 3 |
rhNRG-1;Placebo |
46 |
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure |
Terminated |
NCT01541202 |
Phase 3 |
rhNRG-1;Placebo |
47 |
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Efficacy/Safety of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure |
Terminated |
NCT01439893 |
Phase 3 |
rhNRG-1;Placebo |
48 |
MADIT ASIA Cardiac Resynchronization Trial (MADIT-ASIA) |
Terminated |
NCT01872234 |
Phase 3 |
|
49 |
GutHeart: Targeting Gut Microbiota to Treat Heart Failure |
Unknown status |
NCT02637167 |
Phase 2 |
Rifaximin;Saccharomyces boulardii |
50 |
A Double Blinded, Placebo Controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Acute Cardiovascular Responses of a 7 Day Oral Treatment With the Partial Adenosine A1 Receptor Agonist BAY1067197 in Patients With Chronic Systolic Heart Failure: the PARSiFAL-pilot Study. |
Completed |
NCT02040233 |
Phase 2 |
BAY1067197 (10 mg);BAY1067197;Placebo (10 mg);Placebo |
|